Astellas Hits Sagent, Strides With Adenoscan IP Suit

Law360, Washington (June 21, 2011, 5:39 PM EDT) -- Astellas Pharma US LLC and affiliate Item Development AB hit Sagent Pharmaceuticals Inc. and Strides Arcolab Ltd. with a lawsuit in New Jersey federal court on Tuesday for allegedly violating a patent for the pharmacologic stress agent Adenoscan.

Sagent has filed an Abbreviated New Drug Application with the the U.S. Food and Drug Administration seeking approval to make a generic version of Adenoscan, according to Astellas.

The patent-in-suit is U.S. Patent No. 5,731,296, "a selective vasodilation by continuous adenosine infusion" that is set to expire in March 2015. The patent relates to the use of the prescription drug adenosine as an...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!